DDInter120 DDInter1658
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Arsenic trioxide {u} (Compound) binds {v} (Gene) JUN
Arsenic trioxide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Arsenic trioxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Arsenic trioxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Arsenic trioxide {u} may lead to a major life threatening interaction when taken with {v} Perphenazine
Arsenic trioxide {u} may lead to a major life threatening interaction when taken with {v} Histrelin
Arsenic trioxide (Compound) binds JUN (Gene)
Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Arsenic trioxide may lead to a major life threatening interaction when taken with Perphenazine
Arsenic trioxide may lead to a major life threatening interaction when taken with Histrelin